Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Phase-III-Studie von HMPL-760 in Kombination mit R-GemOx versus Placebo in Kombination mit R-GemOx bei rezidiviertem/refraktärem DLBCL

9. November 2026 aktualisiert von: Hutchmed

Eine Phase-III-randomisierte, doppelblinde, positiv kontrollierte Studie zur Bewertung der Wirksamkeit, Sicherheit und Pharmakokinetik von HMPL-760 in Kombination mit R-GemOx im Vergleich zu Placebo in Kombination mit R-GemOx bei Patienten mit rezidiviertem/refraktärem diffus großzelligen B-Zell-Lymphom (DLBCL)

This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.

Studienübersicht

Detaillierte Beschreibung

The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.

The target population of this study includes patients with DLBCL who are relapsed or refractory.

Studientyp

Interventionell

Einschreibung (Geschätzt)

240

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Baoding, China
        • Rekrutierung
        • Baoding NO.1 Central Hospital
        • Kontakt:
        • Hauptermittler:
          • Haiying Yao
      • Beijing, China
        • Rekrutierung
        • Beijing GoBroad Hospital
        • Hauptermittler:
          • Kai Hu
        • Kontakt:
      • Beijing, China
        • Rekrutierung
        • BEIJING TONGREN HOSPITAL, Capital Medical University
        • Hauptermittler:
          • Liang Wang
        • Kontakt:
      • Bengbu, China
        • Rekrutierung
        • The First Affiliated Hospital of Bengbu Medical College
        • Kontakt:
        • Hauptermittler:
          • Yanli Yang
      • Changchun, China
        • Rekrutierung
        • The First Hospital of Jilin University
        • Hauptermittler:
          • Ou Bai
        • Kontakt:
      • Changsha, China
        • Rekrutierung
        • Hunan Cancer Hospital
        • Hauptermittler:
          • Hui Zhou
        • Kontakt:
      • Changsha, China
        • Rekrutierung
        • The Second Xiangya Hospital of Central South University
        • Hauptermittler:
          • Hongling Peng
        • Kontakt:
      • Changsha, China
        • Rekrutierung
        • People's Hospital of Hunan Province
        • Kontakt:
        • Hauptermittler:
          • Can Liu
      • Chengdu, China
        • Rekrutierung
        • West China Hospital of Sichuan University
        • Hauptermittler:
          • Liqun Zou
        • Kontakt:
      • Chengdu, China
        • Rekrutierung
        • Sichuan Provincial People's Hospital
        • Kontakt:
        • Hauptermittler:
          • Xiaobing Huang
      • Chongqing, China
        • Rekrutierung
        • The First Affiliated Hospital of Chongqing Medical University
        • Hauptermittler:
          • Xin Wang
        • Kontakt:
      • Chongqing, China
        • Rekrutierung
        • Chongqing University Cancer Hospital
        • Hauptermittler:
          • Yao Liu
        • Kontakt:
      • Fujian, China
        • Rekrutierung
        • Quanzhou First Hospital.Fujian
        • Kontakt:
        • Hauptermittler:
          • Xiongpeng Zhu
      • Fuzhou, China
        • Rekrutierung
        • Fujian Medical University Union Hospital
        • Hauptermittler:
          • Jianzhen Shen
        • Kontakt:
      • Guangzhou, China
        • Rekrutierung
        • Sun Yat-sen University Cancer Center
        • Hauptermittler:
          • Zhiming Li
        • Kontakt:
      • Guangzhou, China
        • Rekrutierung
        • Guangdong Provincial People's Hospital
        • Kontakt:
        • Hauptermittler:
          • Xiaojuan Wei
      • Guangzhou, China
        • Rekrutierung
        • ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
        • Hauptermittler:
          • Yuhua Li
        • Kontakt:
      • Guiyang, China
        • Rekrutierung
        • The Affiliated Hospital of Guizhou Medical University
        • Hauptermittler:
          • Yan Zhang
        • Kontakt:
      • Hangzhou, China
        • Rekrutierung
        • Zhejiang Cancer Hospital
        • Hauptermittler:
          • Haiyan Yang
        • Kontakt:
      • Hangzhou, China
        • Rekrutierung
        • The First Affiliated Hospital, Zhejiang University
        • Hauptermittler:
          • Zhen Cai
        • Kontakt:
      • Harbin, China
        • Rekrutierung
        • Harbin Medical University Cancer Hospital
        • Kontakt:
        • Hauptermittler:
          • Qingyuan Zhang
      • Hefei, China
        • Rekrutierung
        • The Second Affiliated Hospital of Anhui Medical University
        • Kontakt:
        • Hauptermittler:
          • Zhimin Zhai
      • Jinan, China
        • Rekrutierung
        • Qilu Hospital of Shandong University
        • Kontakt:
        • Hauptermittler:
          • Shuqian Xu
      • Jinan, China
        • Rekrutierung
        • Shandong Cancer Hospital & Institute
        • Hauptermittler:
          • Zengjun Li
        • Kontakt:
      • Kunming, China
        • Noch keine Rekrutierung
        • The First Affiliated Hospital of Kunming Medical University
        • Kontakt:
        • Hauptermittler:
          • Mingxia Shi
      • Nanchang, China
        • Rekrutierung
        • Jiangxi Cancer Hospital
        • Hauptermittler:
          • Yan Huang
        • Kontakt:
      • Nanjing, China
        • Rekrutierung
        • Jiangsu Cancer Hospital
        • Hauptermittler:
          • Yan Zhang
        • Kontakt:
      • Nanjing, China
        • Rekrutierung
        • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
        • Kontakt:
        • Hauptermittler:
          • Jingyan Xu
      • Nanning, China
        • Rekrutierung
        • The First Affiliated Hospital of Guangxi Medical University
        • Hauptermittler:
          • Zhigang Peng
        • Kontakt:
      • Qingdao, China
        • Rekrutierung
        • The Affiliated Hospital of Qingdao University
        • Kontakt:
        • Hauptermittler:
          • Xia Zhao
      • Shanghai, China
        • Rekrutierung
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • Hauptermittler:
          • Weili Zhao
        • Kontakt:
      • Shanghai, China
        • Rekrutierung
        • Tongji Hospital of Tongji University
        • Kontakt:
        • Hauptermittler:
          • Ping Li
      • Shanghai, China
        • Noch keine Rekrutierung
        • Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
        • Hauptermittler:
          • Ligen Liu
        • Kontakt:
      • Shenyang, China
        • Rekrutierung
        • Shengjing Hospital of China Medical University
        • Hauptermittler:
          • Wei Yang
        • Kontakt:
      • Shenzhen, China
        • Rekrutierung
        • Shenzhen people's hospital
        • Hauptermittler:
          • Jihao Zhou
        • Kontakt:
      • Taiyuan, China
        • Rekrutierung
        • Shanxi Provincial Cancer Hospital
        • Hauptermittler:
          • Liping Su
        • Kontakt:
      • Tangshan, China
        • Rekrutierung
        • North China University of Science and Technology Affiliated Hospital
        • Kontakt:
        • Hauptermittler:
          • Zhenyu Yan
      • Tianjin, China
        • Rekrutierung
        • Tianjin Medical University Cancer Institute & Hospital
        • Hauptermittler:
          • Zhengzi Qian
        • Kontakt:
          • Zhengzi Qian
          • Telefonnummer: 13702031222
          • E-Mail: qzz@163.com
      • Tianjin, China
        • Rekrutierung
        • Tianjin People's Hospital
        • Kontakt:
        • Hauptermittler:
          • Xingli Zhao
      • Tianjin, China
        • Rekrutierung
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
        • Hauptermittler:
          • Dehui Zou
        • Kontakt:
      • Wenzhou, China
        • Rekrutierung
        • The First Affiliated Hospital of WMU
        • Kontakt:
        • Hauptermittler:
          • Songfu Jiang
      • Wuhan, China
        • Rekrutierung
        • Hubei Cancer Hospital
        • Hauptermittler:
          • Huijing Wu
        • Kontakt:
      • Wuhan, China
        • Rekrutierung
        • Wuhan Union Hospital of China
        • Hauptermittler:
          • Liling Zhang
        • Kontakt:
      • Xi'an, China
        • Rekrutierung
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Hauptermittler:
          • Pengcheng He
        • Kontakt:
      • Xi'an, China
        • Rekrutierung
        • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
        • Hauptermittler:
          • Jie Liu
        • Kontakt:
      • Xiamen, China
        • Noch keine Rekrutierung
        • The First Affiliated Hospital of Xiamen University
        • Hauptermittler:
          • Bing Xu
        • Kontakt:
      • Xuzhou, China
        • Rekrutierung
        • The Affiliated Hospital of Xuzhou Medical University
        • Kontakt:
        • Hauptermittler:
          • Wei Sang
      • Zhengzhou, China
        • Rekrutierung
        • Henan Cancer Hospital
        • Hauptermittler:
          • Keshu Zhou
        • Kontakt:
      • Zhengzhou, China
        • Rekrutierung
        • The First Affiliated Hospital of Zhengzhou University
        • Kontakt:
        • Hauptermittler:
          • Xudong Zhang
      • Ürümqi, China
        • Rekrutierung
        • People's Hospital of Xinjiang Uygur Autonomous Region
        • Hauptermittler:
          • Yan Li
        • Kontakt:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Rekrutierung
        • Fudan University Shanghai Cancer Center
        • Kontakt:
        • Hauptermittler:
          • Fangfang Lv

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Sign the ICF and be able to follow the requirements of study protocol;
  2. Age ≥18 years;
  3. ECOG performance status score between 0 and 2;
  4. Histopathologically confirmed diagnosis of DLBCL;
  5. The investigator judges that the patient's current condition requires further treatment;
  6. Patients should have at least one bi-dimensionally measurable lesion;
  7. Expected survival is more than 12 weeks;

Exclusion Criteria:

  1. Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
  2. Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
  3. Organ insufficiency;
  4. Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
  5. History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
  6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
  7. The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
  8. Clinically significant active infection;

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: The experimental group

Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Patients will receive HMPL-760 once daily (QD) orally.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Andere Namen:
  • Gemcitabinhydrochlorid zur Injektion
  • Rituximab-Injektion
  • Oxaliplatin-Injektion
Placebo-Komparator: The control group

Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group.

R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.

Andere Namen:
  • Gemcitabinhydrochlorid zur Injektion
  • Rituximab-Injektion
  • Oxaliplatin-Injektion

Patients will receive HMPL-760 placebo once daily (QD) orally.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Progression-free survival (PFS)
Zeitfenster: Up to approximately two years

Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first.

Up to approximately two years
End of treatment (EOT)
Zeitfenster: Up to approximately two years

Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy).

Up to approximately two years
Systemic antitumor therapy
Zeitfenster: Up to approximately two years

Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy).

Up to approximately two years
Overall survival (OS)
Zeitfenster: Up to approximately two years

OS is defined as the time from randomization to death due to any cause.

Up to approximately two years
systematic anti-tumor therapy
Zeitfenster: Up to approximately two years

OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy).

Up to approximately two years
Premature withdrawal from study treatment
Zeitfenster: Up to approximately two years

OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy).

Up to approximately two years

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Independent review committee (IRC)-assessed PFS
Zeitfenster: Up to approximately two years

Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014).

Up to approximately two years
IRC- and investigator-assessed objective response rate (ORR)
Zeitfenster: Up to approximately two years

Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR)

Up to approximately two years
IRC- and investigator-assessed complete response rate (CRR)
Zeitfenster: Up to approximately two years

Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR)

Up to approximately two years
IRC- and investigator-assessed duration of response (DoR)
Zeitfenster: Up to approximately two years

For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first

Up to approximately two years
IRC- and investigator-assessed clinical benefit rate (CBR)
Zeitfenster: Up to approximately two years

Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD)

Up to approximately two years
IRC- and investigator-assessed time to response (TTR)
Zeitfenster: Up to approximately two years

Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR)

Up to approximately two years
Safety Endpoints
Zeitfenster: Up to approximately two years
  • Incidence and severity of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious adverse events (TESAEs), incidence of TEAEs leading to permanent discontinuation, dose interruption, and dose reduction, and their correlation to study drug. The severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 (NCI CTCAE 6.0).
  • Changes in laboratory tests, vital signs, 12-lead ECG, etc.
Up to approximately two years
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
Zeitfenster: At the end of Cycle 4 (each cycle is 21 days)]

including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis.

At the end of Cycle 4 (each cycle is 21 days)]

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Biomarker assessment
Zeitfenster: Up to approximately two years

Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy.

Up to approximately two years
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
Zeitfenster: Up to approximately two years

Human metabolites of HMPL-760 when co-administered with R-GemOx

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Zeitfenster: Up to approximately two years

maximum concentration in steady-state (Cmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Zeitfenster: Up to approximately two years

time to maximum concentration in steady-state (Tmax,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Zeitfenster: Up to approximately two years

Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss)

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Zeitfenster: Up to approximately two years

The rate at which the drug is eliminated from the body (CL/F) (if applicable )

Up to approximately two years
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
Zeitfenster: Up to approximately two years

The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable)

Up to approximately two years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Weili Zhao, Ruijin Hospital

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

20. März 2026

Primärer Abschluss (Geschätzt)

30. April 2028

Studienabschluss (Geschätzt)

30. Dezember 2028

Studienanmeldedaten

Zuerst eingereicht

28. Januar 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

6. Februar 2026

Zuerst gepostet (Tatsächlich)

13. Februar 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

10. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

9. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren